EP3505158A1 — Pharmaceutical composition of lenalidomide pharmaceutically acceptable acid addition salt
Assigned to KRKA dd · Expires 2019-07-03 · 7y expired
What this patent protects
The present invention provides solid pharmaceutical formulations and methods for making the same, wherein the pharmaceutical formulations comprise lenalidomide in the form of a pharmaceutically acceptable salt. The pharmaceutical formulations of the present invention exhibit supe…
USPTO Abstract
The present invention provides solid pharmaceutical formulations and methods for making the same, wherein the pharmaceutical formulations comprise lenalidomide in the form of a pharmaceutically acceptable salt. The pharmaceutical formulations of the present invention exhibit superior stability especially in terms of disproportionation of the lenalidomide salt: this undesired effect is prevented by incorporating an acid into the formulation and/or by avoiding the use of proton-accepting excipients and/or by selecting a combination of excipients such that the resulting formulation exhibits acidic properties.
Drugs covered by this patent
- Revlimid (lenalidomide) · Bristol-Myers Squibb
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.